ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.480,89
0,21%
S&P 500
5.187,67
0,00%
US Dollar vs BRL
5,091
0,03%
Bitcoin
61.124,15
-0,10%
Brent Oil
83,805
0,29%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cara Therapeutics Inc (CARA)

  7. Cara Therapeutics Inc (CARA) Notícias

CARA

Cara Therapeutics (CARA)

Cara Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CARA
DataHoraFonteTítuloCódigoCompanhia
06/05/202417:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
06/05/202408:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:CARACara Therapeutics Inc
02/04/202408:00GlobeNewswire Inc.Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
07/03/202409:00GlobeNewswire Inc.Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024NASDAQ:CARACara Therapeutics Inc
06/03/202418:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CARACara Therapeutics Inc
04/03/202418:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARACara Therapeutics Inc
04/03/202418:01GlobeNewswire Inc.Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
13/02/202420:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CARACara Therapeutics Inc
12/02/202418:01GlobeNewswire Inc.Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024NASDAQ:CARACara Therapeutics Inc
22/01/202409:00GlobeNewswire Inc.Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026NASDAQ:CARACara Therapeutics Inc
18/12/202309:00GlobeNewswire Inc.Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic DermatitisNASDAQ:CARACara Therapeutics Inc
13/11/202318:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARACara Therapeutics Inc
13/11/202318:01GlobeNewswire Inc.Cara Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare RoyaltyNASDAQ:CARACara Therapeutics Inc
23/10/202308:00GlobeNewswire Inc.Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023NASDAQ:CARACara Therapeutics Inc
25/09/202308:00GlobeNewswire Inc.Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsNASDAQ:CARACara Therapeutics Inc
05/09/202308:00GlobeNewswire Inc.Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CARACara Therapeutics Inc
07/08/202317:01GlobeNewswire Inc.Cara Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
04/08/202318:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
03/08/202308:00GlobeNewswire Inc.Cara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsNASDAQ:CARACara Therapeutics Inc
02/08/202308:00GlobeNewswire Inc.Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:CARACara Therapeutics Inc
24/07/202308:00GlobeNewswire Inc.Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023NASDAQ:CARACara Therapeutics Inc
27/06/202317:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CARACara Therapeutics Inc
02/06/202319:46PR Newswire (US)Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:CARACara Therapeutics Inc
02/06/202317:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CARACara Therapeutics Inc
01/06/202308:00GlobeNewswire Inc.Cara Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
18/05/202303:00PR Newswire (US)Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
18/05/202303:00GlobeNewswire Inc.Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
15/05/202317:01GlobeNewswire Inc.Cara Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
01/05/202308:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023NASDAQ:CARACara Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CARA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
VVEO3
CM Hospitalar ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
JHSF3
JHSF PART ON
BOV
BRKM5
BRASKEM PNA
BOV
PRIO3
PETRORIO ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
ENAT3
ENAUTA ON
BOV
SGPS3
SPRINGS ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados